-
Session to explore GLP-1, GIP RAs in mental disorders, addiction, and more
Roger S. McIntyre, MD, FRCPC, and other investigators will outline unanticipated effects of using incretin receptor agonists outside of the clinical impact on weight loss and metabolic disorders.
-
Experts will provide update on latest advances in pediatric type 2 diabetes
The use of glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors are just two of the new considerations, as panelist Megan Oberle Bensignor, MD, MSHP, will discuss.
-
Panel to spotlight potential of continuous ketone monitoring
Just as continuous glucose monitoring is transforming diabetes care with improved glucose management, continuous ketone monitoring could dramatically improve patient outcomes. Experts, including Ketan Dhatariya, MBBS, MSc, MD, MS, FRCP, PhD, will explain how.
-
MariTide investigators will review trial data for monthly obesity treatment
Among the panelists, Ania M. Jastreboff, MD, PhD, will discuss results for participants without type 2 diabetes, and Harold Bays, MD, will discuss results for participants with the disease.
-
Symposium will discuss QWINT results that could signal paradigm shift in basal insulin dosing
Chantal Mathieu, MD, PhD, and other researchers will explain the latest data from a series of pivotal trials on once-weekly insulin efsitora alfa.
-
Researchers to share PATHWEIGH ‘roadmap’ for implementing weight management processes into primary care
PATHWEIGH focuses on reducing excess body weight and weight-related medical complications by providing patients with highly individualized care based on their needs, access, and preferences.
-
Investigators will present findings from treatment phase of CATALYST trial
Researchers, including Vivian Fonseca, MD, will return to the Scientific Sessions with new data on mifepristone use to treat people with hypercortisolism and difficult-to-manage type 2 diabetes.
-
Session will explore the new frontier of adjunctive therapies in type 1 diabetes
Among the expert panelists, Klara R. Klein, MD, PhD, will explore the role of glucokinase activators in type 1 diabetes and the prevention of hypoglycemia.
-
Researchers to share weight loss results from bimagrumab and semaglutide combo
Steven B. Heymsfield, MD, and other panelists will explain insights into the treatment of obesity and overweight from BELIEVE.
-
Investigators to reveal full results from REDEFINE 1, 2 in Chicago
Melanie J. Davies, MB, ChB, MD, and other researchers will review data on combination therapy for weight loss using a fixed-dose combination of semaglutide and long-acting amylin analogue cagrilintide.